U-Chart Analysis:BIOFERMIN PHARMACEUTICAL CO.,LTD.:4517

※The values of financial statements might be different from the actual ones. Please confirm the original. [instructions]

Main FunctionHelp Company NameHelp CodeHelp Types of IndustryHelp Market Name Fiscal Year End Year of Listing
Browse U-Chart Add to 'Companies Comparison' list Compare Lustrum Ullet index BIOFERMIN PHARMACEUTICAL CO.,LTD. Go to web site 4517 Medicals 1st TSE March 1, 2000 1961.
Analysis u.gifU-Chart AnalysisHelp hikaku.gifAdd to 'Companies Comparison' listHelp u2.gifCompare LustrumHelp mark.gifUllet indexHelp
Accounts Information Balance Sheet Profit and Loss Account Cash Flow Statement
Display

BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet(B/S)

[Show - Hide] U-Chart:Balance Sheet (B/S)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet 2021年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet 2020年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet 2019年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet 2018年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Balance Sheet 2017年3月期

[Show - Hide] Balance Sheet (B/S)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2021 March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017
Cash and Cash Equivalents 14,413 17,800 15,456 14,525 12,800
Other Current AssetsHelp 5,089 4,543 4,723 4,182 4,025
Tangible Fixed AssetsHelp 11,880 8,364 8,736 8,829 9,530
Intangible Fixed AssetHelp 99 86 88 100 101
Investments and OthersHelp 1,904 1,625 2,162 2,318 2,216
Total AssetsHelp 33,385 32,417 31,165 29,954 28,672
Total Current LiabilitiesHelp 2,943 3,008 2,915 3,192 3,154
Total Long-term LiabilitiesHelp 0 2 4 5 0
Shareholder's EquityHelp 30,442 29,408 28,247 26,757 25,518
Total LiabilitiesHelp 33,385 32,417 31,165 29,954 28,672

BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account(P/L)

[表示非表示] U-Chart:Profit and Loss Account (P/L)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2021年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2020年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2019年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2018年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2017年3月期

[Show - Hide] Profit and Loss Account (P/L)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2021 March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017
Amount of Sales 10,811 11,925 11,543 10,877 10,619
Total Sales 10,811 11,925 11,543 10,877 10,619
Cost of SalesHelp 4,497 4,601 4,545 3,769 4,032
Other Costs and RevenueHelp 4,766 5,083 4,693 4,897 4,687
Total CostsHelp 9,263 9,684 9,237 8,667 8,719
Net RevenueHelp 6,314 7,323 6,998 7,108 6,587
Earnings Before TaxHelp 2,121 3,139 3,274 3,108 2,710
Net IncomeHelp 1,548 2,241 2,305 2,211 1,899
Net Income 1,548 2,241 2,305 2,211 1,899

BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement(C/F)

[表示非表示] U-Chart:Cash Flow Statement (C/F)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2021年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2020年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2019年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2018年3月期 BIOFERMIN PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2017年3月期

[Show - Hide] Cash Flow Statement (C/F)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2021 March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017
Operating Cash Flow(OFC)Help 1,922 3,744 2,517 2,987 3,618
Investing Cash Flow(ICF)Help -4,591 -681 -868 -247 -586
Financing Cash FlowHelp -718 -719 -718 -1,015 -716
Exchange Difference of Cash and Cash EquivalentsHelp 0 -0 0 0 -0
Net Increase and Decrease in Cash and Cash Equivalentsn -3,387 2,344 931 1,725 2,316

他社比較Help

Companies in 'Companies Comparison' list

Browsing historyHelp

Your reecently viewed companies

BIOFERMIN PHARMACEUTICAL CO.,LTD.

Company where related level is highHelp

ASKA Pharmaceutical Holdings Co., Ltd.
TAISHO PHARMACEUTICAL CO.,LTD.
Noile-Immune Biotech Inc.
Carna Biosciences,Inc.
KAKEN PHARMACEUTICAL CO.,LTD.
Perseus Proteomics Inc.
R-TECH UENO,LTD.
Kringle Pharma,Inc.
GNI Group Ltd.
TSUMURA & CO.